Market Exclusive

ANTHERA PHARMACEUTICALS, INC. (NASDAQ:ANTH) Files An 8-K Results of Operations and Financial Condition

ANTHERA PHARMACEUTICALS, INC. (NASDAQ:ANTH) Files An 8-K Results of Operations and Financial Condition

Item 2.02

Results of Operations and Financial Condition.
On February 27, 2017, Anthera Pharmaceuticals, Inc. (the Company)
issued its fourth quarter 2016 press release. A copy of the press
release is furnished herewith as Exhibit 99.1.
Item 9.01
Financial Statements and Exhibits.
(d)
Exhibits
Exhibit No.
Description
99.1
Press Release dated February 27, 2017

About ANTHERA PHARMACEUTICALS, INC. (NASDAQ:ANTH)
Anthera Pharmaceuticals, Inc. (Anthera) is a biopharmaceutical company focused on developing and commercializing products to treat serious diseases associated with inflammation, including enzyme replacement therapies and autoimmune diseases. The Company has two Phase III product candidates, liprotamase also known as Sollpura and blisibimod. Sollpura is a non-porcine investigational Pancreatic Enzyme Replacement Therapy (PERT) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (EPI), often seen in patients with cystic fibrosis and other conditions. Blisibimod targets B-cell activating factor (BAFF), which has been shown to be elevated in a range of B-cell mediated autoimmune diseases, including systemic lupus erythematosus (SLE), or lupus, Immunoglobulin A nephropathy (IgA) nephropathy, lupus nephritis and others. ANTHERA PHARMACEUTICALS, INC. (NASDAQ:ANTH) Recent Trading Information
ANTHERA PHARMACEUTICALS, INC. (NASDAQ:ANTH) closed its last trading session up +0.014 at 0.709 with 1,097,733 shares trading hands.

Exit mobile version